Liver cancer has a more aggressive disease course in HIV-positive people co-infected with viral hepatitis
Traditional risk factors strongest predictors of sub-clinical cardiovascular disease in people about to start HIV therapy
HIV and hepatitis C co-infection increases the risk of cognitive impairment
Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising